nach oben

Cardiovascular Drugs and Therapy

Erschienen in:

01.06.2012

Effect of Chronic CPT-1 Inhibition on Myocardial Ischemia-Reperfusion Injury (I/R) in a Model of Diet-Induced Obesity

verfasst von: Gerald Maarman, Erna Marais, Amanda Lochner, Eugene F du Toit

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

By increasing circulating free fatty acids and the rate of fatty acid oxidation, obesity decreases glucose oxidation and myocardial tolerance to ischemia. Partial inhibition of fatty acid oxidation may improve myocardial tolerance to ischemia/reperfusion (I/R) in obesity. We assessed the effects of oxfenicine treatment on post ischemic cardiac function and myocardial infarct size in obese rats.

Methods

Male Wistar rats were fed a control diet or a high calorie diet which resulted in diet induced obesity (DIO) for 16 weeks. Oxfenicine (200 mg/kg/day) was administered to control and DIO rats for the last 8 weeks. Isolated hearts were perfused and infarct size and post ischemic cardiac function was assessed after regional or global ischemia and reperfusion. Cardiac mitochondrial function was assessed and myocardial expression and activity of CPT-1 (carnitine palmitoyl transferase-1) and IRS-1 (insulin receptor substrate-1) was assessed using Western blot analysis.

Results

In the DIO rats, chronic oxfenicine treatment improved post ischemic cardiac function and reduced myocardial infarct size after I/R but had no effect on the cardiac mitochondrial respiration. Chronic oxfenicine treatment worsened post ischemic cardiac function, myocardial infarct size and basal mitochondrial respiration in control rat hearts. Basal respiratory control index (RCI) values, state 2 and state 4 respiration rates and ADP phosphorylation rates were compromised by oxfenicine treatment.

Conclusion

Chronic oxfenicine treatment improved myocardial tolerance to I/R in the obese rat hearts but decreased myocardial tolerance to I/R in control rat hearts. This decreased tolerance to ischemia of oxfenicine treated controls was associated with adverse changes in basal and reoxygenation mitochondrial function. These changes were absent in oxfenicine treated hearts from obese rats.

Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Despés JP. Visceral obesity and the heart. Int J Biochem Cell Biol. 2008;40:821–36.PubMedCrossRef

Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity and metabolism. Circulation. 2006;113:898–918.PubMedCrossRef

Diniz YS, Burneiko RM, Seiva FRF, Almeida FQA, Galhardi CM, Filho JL. Diet compounds, glycemic index and obesity-related cardiac effects. Int J Cardiol. 2008;124:92–9.PubMedCrossRef

Kobayashi H, Nakamura T, Miyaoka K, Nishida M, Funahashi T, Yamashita S, et al. Visceral fat accumulation contributes to insulin resistance, small sized low-density lipoprotein and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ J. 2001;65:193–9.PubMedCrossRef

Thim T, Bentzon JF, Kristiansen SB, Simonsen U, Anderson HL, Wassermann K, et al. Size of myocardial infarction induced by ischemia/reperfusion is unaltered in rats with metabolic syndrome. Clin Sci. 2006;110:665–71.PubMedCrossRef

Hegarty BD, Turner N, Cooney GJ, Kraegen EW. Insulin resistance and fuel homeostasis: the role of AMP-activated protein kinase. Acta Physiol. 2009;196:129–45.CrossRef

Lopaschuk GD, Ussher JR, Folmes CL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207–58.PubMedCrossRef

Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007;101:335–47.PubMedCrossRef

Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim ET Biophys Acta. 2005;1734:112–26.

10.

Opie LH. The heart: physiology and metabolism, second edition Raven Press 1991.

11.

Calvani M, Reda E, Arrigoni-Martelli E. Regulation of carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol. 2000;95:2.CrossRef

12.

Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Research. 1997;34:25–33.CrossRef

13.

Rupp H, Rupp TP, Maisch B. Fatty acid oxidation inhibition with PPAR-α activation (FOXIB/PPARα) for normalizing gene expression in heart failure? Cardiovasc Research. 2005;66:423–6.CrossRef

14.

Taegtmeyer H, Wilson CR, Razeghi P, Sharma S. Metabolic energetics and genetics in the heart. Ann New York Acad Sci. 2005;1047:208–18.CrossRef

15.

Hafstad AD, Khalid AM, How OJ, Larsen TS, Aasum E. Glucose and insulin improve cardiac efficiency and post-ischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endorinol Metab. 2007;292:E1288–94.CrossRef

16.

Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Urban Vogel. 2002;27:621–36.

17.

Beadle RM, Frenneaux M. Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease. Heart. 2010;96:824–30.PubMedCrossRef

18.

Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol. 2009;54:1637–46.PubMedCrossRef

19.

Stephens TW, Higgins AJ, Cook GA, Harris RA. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J. 1985;227:651–60.PubMed

20.

Burges RA, Gardiner DG, Higgins AJ. Protection of the ischemic dog heart by oxfenicine. Life Sci. 1981;29:1847–85.PubMedCrossRef

21.

Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs. 2002;11:615–29.PubMedCrossRef

22.

Okere IC, Chandler MP, McElfresh TA, Rennison JH, Kung TA, Hoit BD, et al. Carnitine palmitoyl transferase-I inhibition is not associated with cardiac hypertrophy in rats fed a high – fat diet. Clin Exp Pharmacol Physiol. 2007;34:113–9.PubMedCrossRef

23.

Bachmann E, Weber E. Biochemical mechanisms of oxfenicine cardio toxicity. Pharmacol. 1988;36:238–48.CrossRef

24.

Jodalen H, Ytrehus K, Moen P, Hokland B, Mjøs OD. Oxfenicine-induced accumulation of lipid in the rat myocardium. J Mol Cell Cardiol. 1988;20:277–82.PubMedCrossRef

25.

Greaves P, Martin J, Michel MC, Mompon P. Cardiac hypertrophy in the dog and rat induced by oxfenicine, an agent which modifies muscle metabolism. Arch Toxicol. 1984;7:488–93.CrossRef

26.

Chang KC, Tseng CD, Lu SC, Liang JT, Wu MS, Tsai MS, et al. Effects of acetyl-L-carnitine and oxfenicine on aorta stiffness in diabetic rats. Eur J Clin Invest. 2010;40:1–9.

27.

Chavez PN, Stanley WC, McElfresh TA, Huang H, Sterk JP, Chandler ME. Effect of hyperglycemia and fatty acid oxidation inhibition during aerobic conditions and demand-induced ischemia. Am J Physiol Heart Circ Physiol. 2003;284:H1521–7.PubMed

28.

Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS, Stanley WC. Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc Research. 2003;59:143–51.CrossRef

29.

Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S, et al. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodelling and delays decompensation in pacing-induced heart failure. Cardiovasc Research. 2005;66:454–61.CrossRef

30.

Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JPH. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Brit J Pharmacol. 1999;128:1570–6.CrossRef

31.

Du Toit EF, Smith W, Muller C, Strijdom H, Stouthammer B, Woodiwiss AJ, et al. Myocardial susceptibility to ischemic-reperfusion injury in a pre-diabetic model of dietary-induced obesity. Am J Physiol Heart Circ Physiol. 2008;294:H2336–43.PubMedCrossRef

32.

Lindenmayer GE, Sordahl LA, Schwartz A. Re-evaluation of oxidative phosphorylation in cardiac mitochondria from normal animals and animals in heart failure. Circ Res. 1968;23:439–50.PubMed

33.

Lanza IR, Nair KS. Functional assessment of isolated mitochondria in vitro. Methods Enzymol. 2009;457:349–72.PubMedCrossRef

34.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265–75.PubMed

35.

Bradford MM. A rapid sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;71:248–54.CrossRef

36.

Higgins AJ, Morville M, Burges RA. Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischemic rat heart. Life Sci. 1980;27:963–70.PubMedCrossRef

37.

Higgins AJ, Morville M, Burges RA. Mechanism of action of oxfenicine on muscle metabolism. Biochem Biophys Res Comm. 1981;100:291–6.PubMedCrossRef

38.

Molaparast-Sales F, Liedtke AJ, Nellis SH. Effects of the fatty acid blocking agents, oxfenicine and 4-bromocrotonic acid, on performance in aerobic and ischemic myocardium. J Mol Cell Cardiol. 1987;19:509–20.CrossRef

39.

Essop MF, Chan WYA, Valle A, García-Palmer FJ, Du Toit EF. Impaired contractile function and mitochondrial respiratory capacity in response to oxygen deprivation in a rat model of pre-diabetes. Acta Physiol. 2009;197:289–96.CrossRef

40.

Zhou L, Huang H, Yuan CL, Keung W, Lopaschuk GD, Stanley WC. Metabolic response to an acute jump in cardiac workload: effects on malonyl-CoA, mechanical efficiency, and fatty acid oxidation. Am J Physiol Heart Circ Physiol. 2008;294:H954–60.PubMedCrossRef

41.

Broderick TL, Glick B. Effect of gender and fatty acids on ischemic recovery of contractile and pump function in the rat heart. Gend Med. 2004;1:86–99.PubMedCrossRef

42.

Carregal M, Varela A, Dalamon V, Sacks S, Savino EA. Beneficial effects of oxfenicine on the hypoxic rat atria. Arch Physiol Biochem. 1995;103:45–9.PubMedCrossRef

43.

Prendes MGM, Garcia JV, Testoni G, Fernandez MA, Perazzo JC, Savino EA, et al. Influence of fasting on the effects of dimethylamiloride and oxfenicine on ischemic–reperfused rat hearts. Arch Physiol Biochem. 2006;112:31–6.CrossRef

44.

Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–9.PubMedCrossRef

45.

Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabet Metab. 1998;14:263–83.CrossRef

46.

Guo L, Tabrizchi R. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol Therap. 2006;111:147–73.CrossRef

47.

King KL, Opie LH. Glucose and glycogen utilization in myocardial ischemia-changes in metabolism and consequences for the myocyte. Mol Cell Biochem. 1998;180:3–26.PubMedCrossRef

48.

Apstein CS, Opie LH. Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value. Cardiovasc Drugs Ther. 1999;13:185–9.PubMedCrossRef

49.

Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med. 1996;37:1723–30.PubMed

50.

Drake-Holland AJ, Passingham JE. The effect of oxfenicine on cardiac carbohydrate metabolism is intact dogs. Bas Res Cardiol. 1983;78:19–27.CrossRef

51.

Barr RL, Lopaschuk GD. Direct measurement of energy metabolism in the isolated working rat heart. JPM. 1997;38:11–7.

52.

Lochner A, Du Toit EF, Huisamen B, Koeslag JH, Moolman JA. Cellular injury in ischemia. Cardiovasc Journ of South Africa. 2004;15:205–6.

53.

Taegtmeyer H. Metabolism — the lost child of cardiology. J Am Coll Cardiol. 2000;36:1386–8.PubMedCrossRef

54.

Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure a randomized, controlled trial of short-term use of a novel treatment. Circ Res. 2005;112:3280–8.

55.

Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK, Larsen TS. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol. 2008;44:201–9.PubMedCrossRef

56.

Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab. 2000;279:E1104–13.PubMed

57.

Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab. 2009;297:E578–91.PubMedCrossRef

58.

Dyck JRB, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, et al. Malonyl-Coenzyme A decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res. 2004;94:e78–84.PubMedCrossRef

59.

Liu Q, Docherty JC, Rendell JCT, Clanachan AS, Lopaschuk GD. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol. 2002;39:718–25.PubMedCrossRef

60.

Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The anti angina drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation inhibiting mitochondrial long chain 3-Ketoacyl Coenzyme A Thiolase. Circ Res. 2000;86:580–8.PubMed

61.

Bielefeld DR, Vary TC, Neely JR. Inhibition of Carnitine Palmitoyl-CoA Transferase activity and fatty acid oxidation by lactate and oxfenicine in cardiac muscle. Mol Cell Cardiol. 1985;17:619–25.

Titel: Effect of Chronic CPT-1 Inhibition on Myocardial Ischemia-Reperfusion Injury (I/R) in a Model of Diet-Induced Obesity
verfasst von: Gerald Maarman
Erna Marais
Amanda Lochner
Eugene F du Toit
Publikationsdatum: 01.06.2012
Verlag: Springer US
Erschienen in: Cardiovascular Drugs and Therapy / Ausgabe 3/2012
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-012-6377-1

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Effect of Chronic CPT-1 Inhibition on Myocardial Ischemia-Reperfusion Injury (I/R) in a Model of Diet-Induced Obesity

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Obesity: a new risk factor for cardiac syndrome X?

Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the Mouse

Thiazolidinedione Drugs Promote Onset, Alter Characteristics, and Increase Mortality of Ischemic Ventricular Fibrillation in Pigs

Pleiotropic Effects of Dronedarone on Ischemia/Reperfusion Injury in Heart and Brain

H2 Mediates Cardioprotection Via Involvements of KATP Channels and Permeability Transition Pores of Mitochondria in Dogs

Interplay Between SAFE and RISK Pathways in Sphingosine-1-Phosphate–Induced Cardioprotection

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie